Amin, M., Minton, S. E., LoRusso, P. M., Krishnamurthi, S. S., Pickett, C. A., Lunceford, J., . . . Lockhart, A. C. (2015). A phase I study of MK-5108, an oral aurora A kinase inhibitor, administered both as monotherapy and in combination with docetaxel, in patients with advanced or refractory solid tumors. Invest New Drugs.
Citação norma ChicagoAmin, Manik, et al. "A Phase I Study of MK-5108, an Oral Aurora A Kinase Inhibitor, Administered Both As Monotherapy and in Combination With Docetaxel, in Patients With Advanced or Refractory Solid Tumors." Invest New Drugs 2015.
ציטוט MLAAmin, Manik, et al. "A Phase I Study of MK-5108, an Oral Aurora A Kinase Inhibitor, Administered Both As Monotherapy and in Combination With Docetaxel, in Patients With Advanced or Refractory Solid Tumors." Invest New Drugs 2015.